MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of “Hold” from Analysts

MaxCyte, Inc. (NASDAQ:MXCT) has received a consensus rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $5.50.

Several equities research analysts recently weighed in on MXCT shares. Wall Street Zen raised shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MaxCyte in a report on Friday, April 24th. Finally, Craig Hallum reduced their price objective on shares of MaxCyte from $7.00 to $5.00 and set a “buy” rating for the company in a report on Wednesday, March 25th.

Institutional Investors Weigh In On MaxCyte

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE lifted its holdings in MaxCyte by 30.1% in the 1st quarter. Bank of America Corp DE now owns 127,258 shares of the company’s stock valued at $89,000 after acquiring an additional 29,457 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in MaxCyte by 153.3% in the 1st quarter. Renaissance Technologies LLC now owns 1,993,200 shares of the company’s stock valued at $1,400,000 after acquiring an additional 1,206,300 shares during the last quarter. Brooklands Fund Management Ltd acquired a new stake in MaxCyte in the 1st quarter valued at about $1,538,000. Bank of New York Mellon Corp lifted its holdings in MaxCyte by 18.3% in the 1st quarter. Bank of New York Mellon Corp now owns 403,937 shares of the company’s stock valued at $284,000 after acquiring an additional 62,477 shares during the last quarter. Finally, Capricorn Fund Managers Ltd acquired a new stake in MaxCyte in the 1st quarter valued at about $5,760,000. 68.81% of the stock is owned by institutional investors and hedge funds.

MaxCyte Stock Up 3.5%

MXCT stock opened at $1.19 on Wednesday. The company has a market capitalization of $127.47 million, a P/E ratio of -3.22 and a beta of 1.48. The company has a 50-day simple moving average of $0.93 and a 200 day simple moving average of $1.08. MaxCyte has a fifty-two week low of $0.64 and a fifty-two week high of $2.38.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.06. The business had revenue of $6.22 million during the quarter, compared to the consensus estimate of $7.28 million. MaxCyte had a negative net margin of 121.16% and a negative return on equity of 20.03%. Equities analysts anticipate that MaxCyte will post -0.3 EPS for the current year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.